Biocon Q1 net profit up 551%, driven by gain from Eris Life partnership

Quick Summary:

Revenue in the biosimilars business grew to Rs 2,083 crore during the period from Rs 2,015 crore earlier.

These milestones will serve as growth catalysts and allow us to expand our reach to millions of patients globally,” said Shreehas Tambe, CEO & Managing Director, Biocon Biologics.

The company reported profit before tax (PBT) of Rs 1,146 crore, up 524 per cent in Q1 FY25.

---

More Pictures

---

Read Quick SummarySave Time

or

Article Details

Category: BusinessFinance

Markets: IndiaAustraliaSouth KoreaMalaysia

Topics: Indian markets Stock markets Pharma companies Biopharma Biocon stock

Source Website Secure: Yes (HTTPS)

News Sentiment: Neutral

Fact Checked: Legitimate

Article Type: News Report

Published On: 2024-08-08 @ 20:50:09 (6 hours ago)

News Timezone: GMT +5:00

News Source URL: business-standard.com

Language: English

Article Length: 640 words

Reading Time: 4 minutes read

Sentences: 23 lines

Sentence Length: 28 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Business Standard

News ID: 21987620

View Article Analysis

About Business Standard

Main Topics: BusinessFinance

Official Website: business-standard.com

Update Frequency: 359 posts per day

Year Established: 1975

Headquarters: India

News Last Updated: 3 hours ago

Coverage Areas: India

Ownership: Independent Company

Publication Timezone: GMT +5:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #49

Publisher Details

Frequently Asked Questions